Hologic announced second quarter fiscal 2025 results, with total revenue of $1.005 billion, a decrease of 0.5% in constant currency, landing at the upper end of its guidance. Non-GAAP earnings per share were $1.03, flat year-over-year and at the high end of the guidance range.
The Diagnostics business grew 1.5% (5.2% excluding COVID-19), driven by BV/CV/TV, respiratory assays, and Biotheranostics, but was offset by reduced HIV testing in Africa due to funding cuts. Breast Health revenue declined 6.9% (9.2% organically), with lower gantry replacements expected for 2025.
Hologic lowered its fiscal 2025 non-GAAP EPS guidance by $0.10 to $4.05-$4.15, while maintaining revenue guidance, primarily due to an anticipated gross impact of $20 million to $25 million per quarter from tariffs, mainly from Costa Rica and China. The company is implementing commercial strategies to drive gantry upgrades and direct sales of Endomagnetics in North America.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.